Bio/Pharma News

Echosens and Novo Nordisk Announce Partnership to Combat NASH

June 27, 2022

The partnership between Echosens and Novo Nordisk is intended to increase awareness and early diagnosis of non-alcoholic steatohepatitis (NASH).

Novartis to Invest $250 Million for R&D of Neglected Tropical Diseases

June 24, 2022

Novartis will endorse the Kigali Declaration on neglected tropical diseases and invest $250 million for R&D.

GSK Announces £1 Billion R&D Investment in Fighting Infectious Diseases in Lower-Income Countries

June 24, 2022

GSK will invest £1 billion in furthering R&D in malaria, tuberculosis, and HIV, as well as neglected tropical diseases.

Kindeva Drug Delivery Completes Acquisition of iPharma Labs

June 22, 2022

Kindeva’s acquisition of iPharma will increase the company’s inhalation formulation outsourcing capabilities.

Orbit Discovery Awarded Innovate UK Grant

June 21, 2022

Orbit Discovery has been awarded the Innovate UK Grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery.

Batavia Biosciences Increases Capacity for Viral Vectors and Vaccine R&D in the Netherlands

June 17, 2022

Batavia Biosciences is expanding its headquarters and R&D capabilities in its Netherlands facility.

Boehringer Ingelheim to Acquire Trutino Biosciences

June 17, 2022

Boehringer Ingelheim has signed an option to acquire Trutino Biosciences.

Precision BioSciences Releases Data on CAR T Therapy Candidates

June 13, 2022

Precision BioSciences has released clinical trial data on CAR T therapy candidates PBCAR0191, PBCAR19B, and PBCAR269A.

Moderna Bivalent Booster Candidate Demonstrates Superior Antibody Response Against Omicron

June 13, 2022

Moderna’s mRNA-1273.214 booster candidate exhibited an eight-fold boost in neutralizing geometric mean titers against Omicron.

REGENXBIO Launches New Gene Therapy Manufacturing Facility in US

June 13, 2022

REGENXBIO has opened a new in-house facility at its headquarters in Rockville, Md., that will be used to manufacture AAV gene therapies at commercial scale.